In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae

被引：22

作者：

Patel, R ^{[1
]}

Rouse, MS ^{[1
]}

Piper, KE ^{[1
]}

Cockerill, FR ^{[1
]}

Steckelberg, JM ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 1998年 / 30卷 / 02期

关键词：

D O I：

10.1016/S0732-8893(97)00207-1

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We report the activity of LY333328 against 35 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes, as determined by PCR), 33 clinical isolates of methicillin-resistant S. aureus, and 29 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by 2 mu g/mL LY333328, and 8 mu g/mL LY333328 suns bactericidal against all isolates tested. All isolates of methicillin-resistant S. aureus were inhibited by 1 mu g/mL LY333328, and 4 mu g/mL LY333328 was bactericidal against all methicillin-resistant S. aureus isolates tested. All isolates of penicillin-resistant S. pneumoniae were inhibited by (0.125 mu g/mL LY333328, and 0.25 mu g/mL LY333328 was bactericidal against all S. pneumoniae isolates tested. LY333328 is a promising new glycopeptide antimicrobial agent. (C) 1998 Elsevier Science Inc.

引用

页码：89 / 92

页数：4

共 11 条

[1]

BALTCH AL, 1996, 36 INT C ANT AG CHEM

[2]

CDC, 1993, MMWR-MORBID MORTAL W, V42, P597

[3] Reductive alkylation of glycopeptide antibiotics: Synthesis and antibacterial activity [J].

Cooper, RDG ;

Snyder, NJ ;

Zweifel, MJ ;

Staszak, MA ;

Wilkie, SC ;

Nicas, TI ;

Mullen, DL ;

Butler, TF ;

Rodriguez, MJ ;

Huff, BE ;

Thompson, RC .

JOURNAL OF ANTIBIOTICS, 1996, 49 (06) :575-581

[4] INVIVO DEVELOPMENT OF TEICOPLANIN RESISTANCE IN A VANB ENTEROCOCCUS-FAECIUM ISOLATE [J].

HAYDEN, MK ;

TRENHOLME, GM ;

SCHULTZ, JE ;

SAHM, DF .

JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) :1224-1227

[5]

MERCIER RC, 1996, 36 INT C ANT AG CHEM

[6] ACTIVITIES OF THE SEMISYNTHETIC GLYCOPEPTIDE LY191145 AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI AND OTHER GRAM-POSITIVE BACTERIA [J].

NICAS, TI ;

MULLEN, DL ;

FLOKOWITSCH, JE ;

PRESTON, DA ;

SNYDER, NJ ;

STRATFORD, RE ;

COOPER, RDG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) :2585-2587

[7]

NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195

[8] Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci [J].

Patel, R ;

Uhl, JR ;

Kohner, P ;

Hopkins, MK ;

Cockerill, FR .

JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (03) :703-707

[9] INDUCIBLE AND CONSTITUTIVE EXPRESSION OF VANC-1-ENCODED RESISTANCE TO VANCOMYCIN IN ENTEROCOCCUS-GALLINARUM [J].

SAHM, DF ;

FREE, L ;

HANDWERGER, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1480-1484

[10] In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci [J].

Schwalbe, RS ;

McIntosh, AC ;

Qaiyumi, S ;

Johnson, JA ;

Johnson, RJ ;

Furness, KM ;

Holloway, WJ ;

SteeleMoore, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2416-2419

← 1 2 →